Overview of EHA's Hemoglobinopathies Initiatives

The EHA Topics-in-Focus Hemoglobinopathies Program  (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.

EHA Grants Hall of Fame

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte  Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.